IBA (Ion Beam Applications S.A.) launched the new Visicoil Twin-Line fiducial marker at the annual meeting of the 2012 American Society for Radiation Oncology (ASTRO).
Older women with early-stage, low-risk breast cancer who were treated with radiation therapy (RT) after breast-conserving surgery (BCS) showed higher cause- specific (CSS) and overall survival (OS) rates than those who did not undergo radiation, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 54th Annual Meeting. The study also found a 6 percent decrease in the use of radiation after 2004 in this population of patients, suggesting that treatment guidelines, which allow for omission of radiation therapy, may need to be re-examined.
McKesson’s solutions for radiology assist customers in meeting today’s challenges with new technology that is designed for easy deployment on multiple devices and in multiple locations, which contributes to a lower cost of ownership and a faster adoption of the technology.
The McKesson Qualitative Intelligence and Communication System (QICS) offering bridges the gaps in communications by providing a comprehensive view of healthcare workflow and correspondence. Utilizing a sophisticated, configurable rules engine, this powerful solution reaches across various healthcare department and IT boundaries to collect, combine and analyze data in powerful, actionable ways.
The McKesson Enterprise Image Repository solution, which is independent from the Horizon Medical Imaging PACS and other PACS, archives and manages image data on behalf of the systems with which it interfaces.
Invivo’s DynaTRIM system is the first commercially available, fully magnetic resonance imaging (MRI)-compatible interventional device for transrectal interventional MRI of the prostate gland.
Invivo’s DynaCAD with ONCAD offers a new way of interpreting magnetic resonance imaging (MRI). ONCAD is the first, fully automated morphological analysis system designed to detect suspicious breast lesions as part of a second check during review of contrast enhanced MRI.
Breast cancer patients who receive radiation treatment do not have a higher risk of long-term cardiac morbidity when compared to patients undergoing modified radical mastectomy (MRM), according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 54th Annual Meeting. This is the first study to document comprehensive, late cardiac outcomes 25 years after breast cancer treatment.
If you enjoy this content, please share it with a colleague
Concurrent use of sorafenib and stereotactic body radiotherapy (SBRT) for advanced liver cancer patients resulted in high toxicity and is not recommended outside of clinical trials, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 54th Annual Meeting. This is the first prospective study of SBRT combined with sorafenib for hepatocellular carcinoma (HCC) patients, and initial outcomes indicate that the dose of sorafenib and the volume of tissue irradiated are key factors in the risk of toxicity; alternative sequencing of therapies should be investigated in future studies.
The Radiological Society of North America's (RSNA) 98th annual scientific assembly is set for Nov. 25-30, 2012, at McCormick Place in Chicago. The event is the largest radiology meeting in the world, with about 60,000 expected to attend. It includes nearly 3,000 educational sessions as well as hundreds of vendors displaying as part of the technical exhibition.
